Vivus beats the street on licensing payments, but investors aren't fooled

Vivus ($VVUS), a go-it-alone marketer with flailing obesity drug Qsymia, is discovering the joys of buddying up. Licensing revenue from agreements for erectile dysfunction drug Stendra cut the company's losses to $0.17 per share, a 70% improvement. But investors looked past licensing revenue to still-flimsy Qsymia sales, which sent shares down by close to 13% in premarket trading Tuesday. More

Suggested Articles

Johnson & Johnson faces a litany of problems, but executives are clearly not concerned—at least not about the company's short-term fortunes.

This week, Goldman Sachs resurrected a burning question: How can pharma companies profit from curing patients with one-time gene and cell therapies?

CMS has determined how it'll pay for Gilead's CAR-T cancer therapy, Yescarta, for outpatient use, but hasn't yet decided on Gilead's…